Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings HUTCHMED (China) Limited Nasdaq

Equities

HCM

US44842L1035

Market Closed - Nasdaq
Other stock markets
 21:00:00 24/05/2024 BST 		5-day change 1st Jan Change
18.73 USD +0.05% Intraday chart for HUTCHMED (China) Limited -7.14% +3.42%
05-24 HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI
05-20 Hutchmed (China) Chairman Resigns, Successor Named MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • With an enterprise value anticipated at 3.38 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HUTCHMED (CHINA) LIMITED Stock HUTCHMED (China) Limited
+3.42% 3.22B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 205B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
A+
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. HCM Stock
  4. HCM Stock
  5. Ratings HUTCHMED (China) Limited